

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A method for inhibition of angiogenesis in a tissue expressing $\alpha 6\beta 4$ integrin, comprising the steps of exposing the tissue to a therapeutic agent effective to reduce the amount of active $\alpha 6\beta 4$ integrin in the tissue, wherein the therapeutic agent targets $\beta 4$.
2. (original) The method of claim 1, wherein the tissue is present in a living organism.
3. (currently amended) The method of claim ~~2~~ ~~4~~, wherein the living organism is human.
4. (original) The method of claim 1, wherein the angiogenesis to be inhibited is pathological angiogenesis.
5. (currently amended) The method of claim 4 ~~any of claims~~ 1 to 4, wherein the therapeutic agent is an antibody.
6. (currently amended) The method of claim 4 ~~any of claims~~ 1 to 4, wherein the therapeutic agent is an RNAi species.
7. (original) A method for treatment of a disease condition associated with pathological angiogenesis in a patient, comprising the step of administering to the patient an amount of a therapeutic agent effective to reduce the amount of active $\alpha 6\beta 4$ integrin, wherein the therapeutic agent targets $\beta 4$.
- 8 (currently amended) The method of claim ~~7~~ ~~8~~ wherein the patient is human.
9. (currently amended) The method of claim 7 ~~or~~ 8, wherein the therapeutic agent is an antibody.
10. (currently amended) The method of claim 7 ~~or~~ 8, wherein the therapeutic agent is an RNAi species.
- 11-14. (canceled)
15. (new) The method of claim 7, wherein the therapeutic agent is an antibody.
16. (new) The method of claim 7, wherein the therapeutic agent is an RNAi species.
17. (new) The method of claim 3, wherein the therapeutic agent is an antibody.

- 18. (new) The method of claim 3, wherein the therapeutic agent is an RNAi species.
- 19. (new) The method of claim 1, wherein the therapeutic agent is an antibody.
- 20. (new) The method of claim 1, wherein the therapeutic agent is an RNAi species.